Serologic and parasitologic evolution post-treatment of patients with recent chronic Chagas disease

[1]  N. Gonzalez,et al.  EVALUACION A 24 MESES POST-TRATAMIENTO CON BENZNIDAZOL EN NINOS DE 6 A 12 ANOS INFECTADOS CON Tiypanosoma cruzi , 2008 .

[2]  A. Rassi,et al.  TRATAMIENTO ESPECIFICO DE LA ENFERMEDAD DE CHAGAS EN LA FASE CRONICA: CRITERIOS DE CURA CONVENCIONALES: XENODIAGNOSTICO, HEMOCULTIVO Y SEROLOGIA , 2007 .

[3]  M. Maldonado,et al.  Seroprevalence and sociocultural conditionants of Chagas disease in school-aged children of marginal zones of Asunción. , 1998, Revista da Sociedade Brasileira de Medicina Tropical.

[4]  Á. Moncayo.  Progress towards the elimination of transmission of Chagas disease in Latin America. , 1997, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[5]  E. Segura,et al.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. , 1994, American heart journal.

[6]  J. Scharfstein,et al.  Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. , 1993, The American journal of tropical medicine and hygiene.

[7]  Z. Brener,et al.  Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  M. Camargo.  Fluorescent antibody test for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. , 1966, Revista do Instituto de Medicina Tropical de Sao Paulo.